Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3995)
All Articles published online
|
Mar 15, 2004 (publication date) through Apr 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10(6): 894-898 [PMID: 15040040 DOI: 10.3748/wjg.v10.i6.894] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i6/894.htm |
| Number | Citing Articles |
| 1 |
Chang Wang, Ying Shi, Xiaomei Wang, Heming Ma, Quan Liu, Yanhang Gao, Junqi Niu. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.940688
|
| 2 |
J Trottier, M Perreault, I Rudkowska, C Levy, A Dallaire-Theroux, M Verreault, P Caron, B Staels, M-C Vohl, R J Straka, O Barbier. Profiling Serum Bile Acid Glucuronides in Humans: Gender Divergences, Genetic Determinants, and Response to Fenofibrate. Clinical Pharmacology & Therapeutics 2013; 94(4): 533 doi: 10.1038/clpt.2013.122
|
| 3 |
C. Levy, J. A. Peter, D. R. Nelson, J. Keach, J. Petz, R. Cabrera, V. Clark, R. J. Firpi, G. Morelli, C. Soldevila-Pico, K. Lindor. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Alimentary Pharmacology & Therapeutics 2011; 33(2): 235 doi: 10.1111/j.1365-2036.2010.04512.x
|
| 4 |
Duminda Suraweera, Harman Rahal, Melissa Jimenez, Matthew Viramontes, Gina Choi, Sammy Saab. Treatment of primary biliary cholangitis ursodeoxycholic acid non‐responders: A systematic review. Liver International 2017; 37(12): 1877 doi: 10.1111/liv.13477
|
| 5 |
Cyril Bigo, Sarah Caron, Amélie Dallaire-Théroux, Olivier Barbier. Nuclear receptors and endobiotics glucuronidation: the good, the bad, and the UGT. Drug Metabolism Reviews 2013; 45(1): 34 doi: 10.3109/03602532.2012.751992
|
| 6 |
Nobuyuki Baba, Haruhiko Kobashi, Kazuhide Yamamoto, Ryo Terada, Takahiro Suzuki, Tomomi Hakoda, Nobuaki Okano, Noriaki Shimada, Shin-Ichi Fujioka, Yoshiaki Iwasaki, Yasushi Shiratori. Gene expression profiling in biliary epithelial cells of primary biliary cirrhosis using laser capture microdissection and cDNA microarray. Translational Research 2006; 148(3): 103 doi: 10.1016/j.trsl.2006.04.007
|
| 7 |
Virginia C. Clark, Cynthia Levy. Cholestatic Liver Disease. 2008; : 45 doi: 10.1007/978-1-59745-118-5_3
|
| 8 |
Sabela Lens, María Leoz, Leyla Nazal, Miguel Bruguera, Albert Parés. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver International 2014; 34(2): 197 doi: 10.1111/liv.12290
|
| 9 |
Mehmet Cindoruk, Mustafa Kerem, Tarkan Karakan, Bulent Salman, Okan Akin, Murat Alper, Ozlem Erdem, Selahattin Ünal. Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterology 2007; 7(1) doi: 10.1186/1471-230X-7-44
|
| 10 |
Claudia O. Zein, Keith D. Lindor. Latest and Emerging Therapies for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Current Gastroenterology Reports 2010; 12(1): 13 doi: 10.1007/s11894-009-0079-2
|
| 11 |
Christophe Corpechot, Olivier Chazouillères, Alexandra Rousseau, Antonia Le Gruyer, François Habersetzer, Philippe Mathurin, Odile Goria, Pascal Potier, Anne Minello, Christine Silvain, Armand Abergel, Maryline Debette-Gratien, Dominique Larrey, Olivier Roux, Jean-Pierre Bronowicki, Jérôme Boursier, Victor de Ledinghen, Alexandra Heurgue-Berlot, Eric Nguyen-Khac, Fabien Zoulim, Isabelle Ollivier-Hourmand, Jean-Pierre Zarski, Gisèle Nkontchou, Sara Lemoinne, Lydie Humbert, Dominique Rainteau, Guillaume Lefèvre, Luc de Chaisemartin, Sylvie Chollet-Martin, Farid Gaouar, Farid-Hakeem Admane, Tabassome Simon, Raoul Poupon. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine 2018; 378(23): 2171 doi: 10.1056/NEJMoa1714519
|
| 12 |
Xiao Feng HAN, Qi Xia WANG, Yuan LIU, Zheng Rui YOU, Zhao Lian BIAN, De Kai QIU, Xiong MA. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. Journal of Digestive Diseases 2012; 13(4): 219 doi: 10.1111/j.1751-2980.2012.00574.x
|
| 13 |
Frank Czul, Cynthia Levy. Novel Therapies on Primary Biliary Cirrhosis. Clinics in Liver Disease 2016; 20(1): 113 doi: 10.1016/j.cld.2015.08.006
|
| 14 |
Elizabeth J Carey, Keith D Lindor. Current pharmacotherapy for cholestatic liver disease. Expert Opinion on Pharmacotherapy 2012; 13(17): 2473 doi: 10.1517/14656566.2012.736491
|
| 15 |
Guidelines for the management of primary biliary cirrhosis. Hepatology Research 2014; 44(S1): 71 doi: 10.1111/hepr.12270
|
| 16 |
Yan Li, Lun-Gen Lu. Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases. Journal of Clinical and Translational Hepatology 2018; 6(4): 1 doi: 10.14218/JCTH.2018.00025
|
| 17 |
Zhigan Jiang, Xing Liu, Zhiliang Yuan, Haiying He, Jing Wang, Xiao Zhang, Zhen Gong, Lijuan Hou, Liang Shen, Fengxun Guo, Jiliang Zhang, Jianhua Wang, Deming Xu, Zhuowei Liu, Haijun Li, Xiaoxin Chen, Chaofeng Long, Jian Li, Shuhui Chen. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. ACS Medicinal Chemistry Letters 2019; 10(7): 1068 doi: 10.1021/acsmedchemlett.9b00189
|
| 18 |
Chunlei Li, Kunyu Zheng, Yiran Chen, Chengmei He, Suying Liu, Yunjiao Yang, Mengtao Li, Xiaofeng Zeng, Li Wang, Fengchun Zhang. A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. Therapeutic Advances in Chronic Disease 2022; 13: 204062232211141 doi: 10.1177/20406223221114198
|
| 19 |
Annarosa Floreani, Ying Sun, Zheng Sheng Zou, Baosen Li, Nora Cazzagon, Christopher L. Bowlus, M. Eric Gershwin. Proposed therapies in primary biliary cholangitis. Expert Review of Gastroenterology & Hepatology 2016; 10(3): 371 doi: 10.1586/17474124.2016.1121810
|
| 20 |
Kathy Senekeo-Effenberger, Shujuan Chen, Erin Brace-Sinnokrak, Jessica A. Bonzo, Mei-Fei Yueh, Upendra Argikar, Jenny Kaeding, Jocelyn Trottier, Rory P. Remmel, Joseph K. Ritter, Olivier Barbier, Robert H. Tukey. Expression of the HumanUGT1Locus in Transgenic Mice by 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic Acid (WY-14643) and Implications on Drug Metabolism through Peroxisome Proliferator-Activated Receptor α Activation. Drug Metabolism and Disposition 2007; 35(3): 419 doi: 10.1124/dmd.106.013243
|
| 21 |
David Sullivan, Barry Lewis. A classification of lipoprotein disorders:implications for clinical management. Clinical Lipidology 2011; 6(3): 327 doi: 10.2217/clp.11.24
|
| 22 |
Akira Honda, Atsushi Tanaka, Tetsuji Kaneko, Atsumasa Komori, Masanori Abe, Mie Inao, Tadashi Namisaki, Naoaki Hashimoto, Kazuhito Kawata, Atsushi Takahashi, Masashi Ninomiya, Jong‐Hon Kang, Mie Arakawa, Satoshi Yamagiwa, Satoru Joshita, Takeji Umemura, Ken Sato, Akira Kaneko, Kentaro Kikuchi, Jun Itakura, Takako Nomura, Keisuke Kakisaka, Hideki Fujii, Norifumi Kawada, Yasuhiro Takikawa, Tsutomu Masaki, Hiromasa Ohira, Satoshi Mochida, Hitoshi Yoshiji, Satoshi Iimuro, Yasushi Matsuzaki, Hajime Takikawa. Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology 2019; 70(6): 2035 doi: 10.1002/hep.30552
|
| 23 |
Xuan Guoyun, Ding Dawei, Liu Ning, Hu Yinan, Yang Fangfang, Tian Siyuan, Sun Hao, Yang Jiaqi, Xu Ang, Guo Guanya, Chen Xi, Shang Yulong, Han Ying. Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.948362
|
| 24 |
Frans J.C. Cuperus, Emina Halilbasic, Michael Trauner. Fibrate treatment for primary biliary cirrhosis. Current Opinion in Gastroenterology 2014; 30(3): 279 doi: 10.1097/MOG.0000000000000056
|
| 25 |
Annarosa Floreani, Irene Franceschet, Lisa Perini, Nora Cazzagon, M. Eric Gershwin, Christopher L. Bowlus. New Therapies for Primary Biliary Cirrhosis. Clinical Reviews in Allergy & Immunology 2015; 48(2-3): 263 doi: 10.1007/s12016-014-8456-5
|
| 26 |
Nisanne S. Ghonem, James L. Boyer. Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come. Hepatology 2013; 57(5): 1691 doi: 10.1002/hep.26155
|
| 27 |
Chung-Heng Liu, Christopher L. Bowlus. Treatment of Primary Biliary Cholangitis. Clinics in Liver Disease 2022; 26(4): 705 doi: 10.1016/j.cld.2022.06.012
|
| 28 |
Seyed Fazel Nabavi, Maria Daglia, Akbar Hajizadeh Moghaddam, Solomon Habtemariam, Seyed Mohammad Nabavi. Curcumin and Liver Disease: from Chemistry to Medicine. Comprehensive Reviews in Food Science and Food Safety 2014; 13(1): 62 doi: 10.1111/1541-4337.12047
|
| 29 |
Haifu Zhang, Shuojun Li, Yonghang Feng, Qinxia Zhang, Biyun Xie. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis. Clinical and Experimental Medicine 2022; 23(5): 1741 doi: 10.1007/s10238-022-00904-2
|
| 30 |
Alexey Sorokin, Jennifer L. Brown, Paul D. Thompson. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis 2007; 194(2): 293 doi: 10.1016/j.atherosclerosis.2006.11.036
|
| 31 |
|
| 32 |
E.N Liberopoulos, M Florentin, M.S Elisaf, D.P Mikhailidis, E Tsianos. Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study. The Open Cardiovascular Medicine Journal 2010; 4(1): 120 doi: 10.2174/1874192401004010120
|
| 33 |
D. Hajdu, K. Aiglová, I. Vinklerová, K. Urbánek. Acute cholestatic hepatitis induced by fenofibrate. Journal of Clinical Pharmacy and Therapeutics 2009; 34(5): 599 doi: 10.1111/j.1365-2710.2009.01029.x
|
| 34 |
D. A. H. ELFAKI, E. BJORNSSON, K. D. LINDOR. Review article: nuclear receptors and liver disease – current understanding and new therapeutic implications. Alimentary Pharmacology & Therapeutics 2009; 30(8): 816 doi: 10.1111/j.1365-2036.2009.04104.x
|
| 35 |
Atsushi Tanaka, M. Eric Gershwin. The Autoimmune Diseases. 2020; : 1149 doi: 10.1016/B978-0-12-812102-3.00058-0
|
| 36 |
Kazufumi Dohmen, Hiroshi Yamamoto, Asataro Yamamoto, Shin-ya Onohara, Shinichi Aishima, Shinji Shimoda. Two cases of primary biliary cholangitis associated with autoimmune hemolytic anemia. Kanzo 2021; 62(3): 144 doi: 10.2957/kanzo.62.144
|
| 37 |
Kazufumi Dohmen, Chun Yang Wen, Shinya Nagaoka, Koji Yano, Seigo Abiru, Toshihito Ueki, Atsumasa Komori, Manabu Daikoku, Hiroshi Yatsuhashi, Hiromi Ishibashi. Fenofibrate-induced liver injury. World Journal of Gastroenterology 2005; 11(48): 7702-7703 doi: 10.3748/wjg.v11.i48.7702
|
| 38 |
Vasiliy Ivanovich Reshetnyak. Concept on the pathogenesis and treatment of primary biliary cirrhosis. World Journal of Gastroenterology 2006; 12(45): 7250-7262 doi: 10.3748/wjg.v12.i45.7250
|
| 39 |
Anna Reig, Pilar Sesé, Albert Parés. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. American Journal of Gastroenterology 2018; 113(1): 49 doi: 10.1038/ajg.2017.287
|
| 40 |
Atsushi Tanaka. Current understanding of primary biliary cholangitis. Clinical and Molecular Hepatology 2021; 27(1): 1 doi: 10.3350/cmh.2020.0028
|
| 41 |
Ulrich Beuers, Gerd A. Kullak-Ublick, Thomas Pusl, Erik R. Rauws, Christian Rust. Medical Treatment of Primary Sclerosing Cholangitis: A Role for Novel Bile Acids and other (post-)Transcriptional Modulators?. Clinical Reviews in Allergy & Immunology 2009; 36(1): 52 doi: 10.1007/s12016-008-8085-y
|
| 42 |
Kenichi Hosonuma, Ken Sato, Yuichi Yamazaki, Masatoshi Yanagisawa, Hiroaki Hashizume, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Masanobu Yamada. A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia. American Journal of Gastroenterology 2015; 110(3): 423 doi: 10.1038/ajg.2015.20
|
| 43 |
Keri-Ann Buchanan-Peart, Cynthia Levy. Novel Therapies in Primary Biliary Cholangitis. Clinics in Liver Disease 2022; 26(4): 747 doi: 10.1016/j.cld.2022.06.013
|
| 44 |
Jocelyn Trottier, Piotr Milkiewicz, Jenny Kaeding, Mélanie Verreault, Olivier Barbier. Coordinate Regulation of Hepatic Bile Acid Oxidation and Conjugation by Nuclear Receptors. Molecular Pharmaceutics 2006; 3(3): 212 doi: 10.1021/mp060020t
|
| 45 |
J Trottier, P Caron, R J Straka, O Barbier. Profile of Serum Bile Acids in Noncholestatic Volunteers: Gender-Related Differences in Response to Fenofibrate. Clinical Pharmacology & Therapeutics 2011; 90(2): 279 doi: 10.1038/clpt.2011.124
|
| 46 |
Francesca Colapietro, M. Eric Gershwin, Ana Lleo. PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales. Journal of Translational Autoimmunity 2023; 6: 100188 doi: 10.1016/j.jtauto.2023.100188
|
| 47 |
Pietro Invernizzi, M. Eric Gershwin. New therapeutics in primary biliary cirrhosis: will there ever be light?. Liver International 2014; 34(2): 167 doi: 10.1111/liv.12354
|
| 48 |
Marina G. Silveira. Cholestatic Liver Disease. Clinical Gastroenterology 2014; : 33 doi: 10.1007/978-1-4939-1013-7_3
|
| 49 |
Hiromi Ishibashi, Yasuni Nakanuma, Yoshiyuki Ueno, Hiroto Egawa, Kazuhiko Koike, Atsumasa Komori, Shotaro Sakisaka, Shinji Shimoda, Ken Shirabe, Mikio Zeniya, Yuji Soejima, Yasuaki Takeyama, Atsushi Tanaka, Makoto Nakamuta, Minoru Nakamura, Kenichi Harada, Nobuyoshi Fukushima, Yoshihiko Maehara, Toshio Morizane, Hirohito Tsubouchi. Clinical Guideline of Primary Biliary Cirrhosis 2012 The Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Kanzo 2012; 53(10): 633 doi: 10.2957/kanzo.53.633
|
| 50 |
Atsushi Tanaka, Patrick S. C. Leung, Christopher L. Bowlus, M. Eric Gershwin. Liver Immunology. 2020; : 335 doi: 10.1007/978-3-030-51709-0_22
|
| 51 |
Kimberly A. Wong, Runalia Bahar, Chung H. Liu, Christopher L. Bowlus. Current Treatment Options for Primary Biliary Cholangitis. Clinics in Liver Disease 2018; 22(3): 481 doi: 10.1016/j.cld.2018.03.003
|
| 52 |
Genovefa D Kolovou, Peggy M Kostakou, Katherine K Anagnostopoulou, Dennis V Cokkinos. Therapeutic Effects of Fibrates in Postprandial Lipemia. American Journal of Cardiovascular Drugs 2008; 8(4): 243 doi: 10.2165/00129784-200808040-00004
|
| 53 |
You-Hyun Lee, Chan-Hee Lee, Jisoo Lee. Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout. The Korean Journal of Internal Medicine 2006; 21(2): 89 doi: 10.3904/kjim.2006.21.2.89
|
| 54 |
Kazufumi Dohmen, Hirofumi Tanaka, Masatora Haruno, Shin-ichi Aishima, Shinji Shimoda. A case of autoimmune hepatitis/primary biliary cirrhosis overlap syndrome progressing rapidly to cirrhosis with skin pigmentation and various immunological characteristics. Kanzo 2010; 51(9): 513 doi: 10.2957/kanzo.51.513
|
| 55 |
Gideon M. Hirschfield, Christopher L. Bowlus, Marlyn J. Mayo, Andreas E. Kremer, John M. Vierling, Kris V. Kowdley, Cynthia Levy, Alejandra Villamil, Alma L. Ladrón de Guevara Cetina, Ewa Janczewska, Ehud Zigmond, Sook-Hyang Jeong, Yusuf Yilmaz, Yiannis Kallis, Christophe Corpechot, Peter Buggisch, Pietro Invernizzi, Maria Carlota Londoño Hurtado, Sandrin Bergheanu, Ke Yang, Yun-Jung Choi, Daria B. Crittenden, Charles A. McWherter. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. New England Journal of Medicine 2024; 390(9): 783 doi: 10.1056/NEJMoa2312100
|
| 56 |
Alla Y. Grigorian, Houssam E. Mardini, Christophe Corpechot, Raoul Poupon, Cynthia Levy. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2015; 39(3): 296 doi: 10.1016/j.clinre.2015.02.011
|
| 57 |
Munechika Enjoji, Ryoko Yada, Tatsuya Fujino, Tsuyoshi Yoshimoto, Masayoshi Yada, Naohiko Harada, Nobito Higuchi, Masaki Kato, Motoyuki Kohjima, Akinobu Taketomi, Yoshihiko Maehara, Manabu Nakashima, Kazuhiro Kotoh, Makoto Nakamuta. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatology International 2009; 3(3): 490 doi: 10.1007/s12072-009-9137-y
|
| 58 |
John S Halliday, Roger W Chapman. No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!. Journal of Gastroenterology and Hepatology 2011; 26(9): 1345 doi: 10.1111/j.1440-1746.2011.06837.x
|
| 59 |
Albert Parés. Advances in treatment options for patients with primary biliary cholangitis. Expert Opinion on Orphan Drugs 2017; 5(11): 847 doi: 10.1080/21678707.2017.1394840
|
| 60 |
Paulo Lisboa Bittencourt, Eduardo Luiz Rachid Cançado, Cláudia Alves Couto, Cynthia Levy, Gilda Porta, Antônio Eduardo Benedito Silva, Debora Raquel Benedita Terrabuio, Roberto José de Carvalho Filho, Dalton Marques Chaves, Irene Kazue Miura, Liana Codes, Luciana Costa Faria, Andreia Silva Evangelista, Alberto Queiroz Farias, Luciana Lofêgo Gonçalves, Michele Harriz, Edmundo Pessoa A Lopes Neto, Gustavo Oliveira Luz, Patrícia Oliveira, Elze Maria Gomes de Oliveira, Janaina Luz Narciso Schiavon, Tiago Seva-Pereira, Edison Roberto Parise. Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. Arquivos de Gastroenterologia 2015; 52(suppl 1): 15 doi: 10.1590/s0004-28032015000500002
|
| 61 |
Gargi Dixit, Arati Prabhu. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics. Experimental and Molecular Pathology 2022; 124: 104723 doi: 10.1016/j.yexmp.2021.104723
|
| 62 |
Kazufumi Dohmen, Shin-ya Onohara, Shigeru Harada. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis. The Korean Journal of Gastroenterology 2021; 78(4): 227 doi: 10.4166/kjg.2021.092
|
| 63 |
Michael Chew, Christopher L. Bowlus. Primary biliary cholangitis: Diagnosis and treatment. Liver Research 2018; 2(2): 81 doi: 10.1016/j.livres.2018.03.004
|
| 64 |
Jocelyn Trottier, Mélanie Verreault, Susan Grepper, Didier Monté, Julie Bélanger, Jenny Kaeding, Patrick Caron, Ted T. Inaba, Olivier Barbier. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 2006; 44(5): 1158 doi: 10.1002/hep.21362
|
| 65 |
Eirini I Rigopoulou, Dimitrios P Bogdanos. Role of autoantibodies in the clinical management of primary biliary cholangitis. World Journal of Gastroenterology 2023; 29(12): 1795-1810 doi: 10.3748/wjg.v29.i12.1795
|
| 66 |
Atsushi Tanaka. Emerging novel treatments for autoimmune liver diseases. Hepatology Research 2019; 49(5): 489 doi: 10.1111/hepr.13347
|
| 67 |
Frank Czul, Adam Peyton, Cynthia Levy. Primary Biliary Cirrhosis. Clinics in Liver Disease 2013; 17(2): 229 doi: 10.1016/j.cld.2012.12.003
|
| 68 |
Andres F. Carrion, Keith D. Lindor, Cynthia Levy. Safety of fibrates in cholestatic liver diseases. Liver International 2021; 41(6): 1335 doi: 10.1111/liv.14871
|
| 69 |
Li Wang, Feng-Chun Zhang, Xuan Zhang. Therapeutic advances for primary biliary cholangitis: the old and the new. European Journal of Gastroenterology & Hepatology 2016; 28(6): 615 doi: 10.1097/MEG.0000000000000591
|
| 70 |
Amitkumar Patel, Anil Seetharam. Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics. Journal of Clinical and Experimental Hepatology 2016; 6(4): 311 doi: 10.1016/j.jceh.2016.10.001
|
| 71 |
Qi Zhao, Rui Yang, Jing Wang, Dan-Dan Hu, Fei Li. PPARα activation protects against cholestatic liver injury. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10524-6
|
| 72 |
Nahum Méndez-Sánchez, Carlos E. Coronel-Castillo, Ana L. Ordoñez-Vázquez. Current Therapies for Cholestatic Diseases. Biomedicines 2023; 11(6): 1713 doi: 10.3390/biomedicines11061713
|
| 73 |
Emina Halilbasic, Anna Baghdasaryan, Michael Trauner. Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases. Clinics in Liver Disease 2013; 17(2): 161 doi: 10.1016/j.cld.2012.12.001
|
| 74 |
Vinod S. Hegade, Amardeep Khanna, Lucy J. Walker, Lin-Lee Wong, Jessica K. Dyson, David E. J. Jones. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. Digestive Diseases and Sciences 2016; 61(10): 3037 doi: 10.1007/s10620-016-4250-y
|
| 75 |
|
| 76 |
Maren H. Harms, Henk R. van Buuren, Adriaan J. van der Meer. Improving prognosis in primary biliary cholangitis – Therapeutic options and strategy. Best Practice & Research Clinical Gastroenterology 2018; : 85 doi: 10.1016/j.bpg.2018.06.004
|
| 77 |
Lucy J. Walker, Julia Newton, David E. J. Jones, Margaret F. Bassendine. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009; 49(1): 337 doi: 10.1002/hep.22670
|
| 78 |
Ming-Ling Chang, Wei-Ting Chen, Tien-Ming Chan, Cheng-Yu Lin, Ming-Yu Chang, Shiang-Chi Chen, Rong-Nan Chien. Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.869018
|
| 79 |
Weijia Duan, Xiaojuan Ou, Xiaoming Wang, Yu Wang, Xinyan Zhao, Qianyi Wang, Xiaoning Wu, Wei Zhang, Hong Ma, Hong You, Jidong Jia. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Revista Española de Enfermedades Digestivas 2018; 110 doi: 10.17235/reed.2018.5533/2018
|